FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088101006> ?p ?o ?g. }

• W2088101006 endingPage "878" @default.
• W2088101006 startingPage "866" @default.
• W2088101006 abstract "CHF3381 [n-(2-indanyl)-glycinamide hydrochloride] has been selected on the basis of a screening program as the compound displaying the highest anticonvulsant activity in the maximal electroshock seizure (MES) test and the best therapeutic index with reference to the rotarod test in mice and rats. In this study, the antiepileptic activity and the behavioural toxicity of CHF3381 were characterised in multiple model systems. CHF3381 effectively prevented MES-induced convulsions when administered i.p. (ED50, 24 mg/kg and 7.5 mg/kg) or p.o. (ED50, 21 mg/kg and 21 mg/kg) in both mice and rats, respectively. The time course of oral anti-MES activity in the rat was related to the brain concentration profile of unchanged CHF3381. Interestingly, the brain drug levels were about 4-5 times higher than in plasma. CHF3381 was very effective in mice against picrotoxin-, and i.c.v. N-methyl-D-aspartate (NMDA)-induced hind limb tonic extension (ED50 Approximately/=10 mg/kg), but was a weaker antagonist of 4-amynopyridine- and bicuculline-induced tonic seizures (ED50 approximately/=100 mg/kg), and ineffective against pentylentetrazole- and picrotoxin-induced clonic seizures. CHF3381 antagonised the behavioural effects and lethality of i.p. administered NMDA (ED50 = 57 mg/kg p.o.), indicating that the compound may act as a functional NMDA antagonist. In keeping with this idea, CHF3381 weakly displaced [(3)H]-TCP from binding to NMDA receptor channels (Ki, 8.8 microM). In the rat amygdala kindling model, CHF3381 was more efficient against kindling development than against kindled seizures (minimally active dose = 80 vs. 120 mg/kg i.p). Furthermore, it significantly increased the seizure threshold in kindled rats at relatively low doses (40 mg/kg i.p.). In contrast with MK-801-induced hyperactivity, CHF3381 moderately reduced the spontaneous locomotor activity in mice at anticonvulsant doses. Toxic effects on motor performance (rotarod test) were found at high doses only (TD50 approximately/= 300 mg/kg p.o., congruent with 100 mg/kg i.p. in both mice and rats). Furthermore, CHF3381 did not impair passive avoidance and Morris water maze responding in the therapeutic range of doses. Finally, the development of tolerance after repeated doses was negligible. These data indicate that CHF3381 exerts anticonvulsant and antiepileptogenic effects in various seizure models and possesses good therapeutic window, with scarce propensity to cause neurological side-effects." @default.
• W2088101006 created "2016-06-24" @default.
• W2088101006 creator A5003015448 @default.
• W2088101006 creator A5003358525 @default.
• W2088101006 creator A5039256755 @default.
• W2088101006 creator A5080564460 @default.
• W2088101006 creator A5082246152 @default.
• W2088101006 creator A5088410101 @default.
• W2088101006 creator A5091230475 @default.
• W2088101006 date "2001-06-01" @default.
• W2088101006 modified "2023-09-23" @default.
• W2088101006 title "Preclinical Evaluation of CHF3381 as a Novel Antiepileptic Agent" @default.
• W2088101006 cites W1158795443 @default.
• W2088101006 cites W1567544633 @default.
• W2088101006 cites W1575233224 @default.
• W2088101006 cites W1966224996 @default.
• W2088101006 cites W1969764460 @default.
• W2088101006 cites W1971815377 @default.
• W2088101006 cites W1974728729 @default.
• W2088101006 cites W1975911537 @default.
• W2088101006 cites W1980916548 @default.
• W2088101006 cites W1982705853 @default.
• W2088101006 cites W1998883371 @default.
• W2088101006 cites W2020789218 @default.
• W2088101006 cites W2028884770 @default.
• W2088101006 cites W2030362820 @default.
• W2088101006 cites W2039676019 @default.
• W2088101006 cites W2043542930 @default.
• W2088101006 cites W2047744286 @default.
• W2088101006 cites W2052795247 @default.
• W2088101006 cites W2057727265 @default.
• W2088101006 cites W2061407496 @default.
• W2088101006 cites W2067686370 @default.
• W2088101006 cites W2072563098 @default.
• W2088101006 cites W2075125615 @default.
• W2088101006 cites W2078922651 @default.
• W2088101006 cites W2082279749 @default.
• W2088101006 cites W2095171239 @default.
• W2088101006 cites W2097635332 @default.
• W2088101006 cites W2103946141 @default.
• W2088101006 cites W2145056858 @default.
• W2088101006 cites W2146329326 @default.
• W2088101006 cites W2245167357 @default.
• W2088101006 cites W4251662319 @default.
• W2088101006 cites W4372151917 @default.
• W2088101006 doi "https://doi.org/10.1016/s0028-3908(01)00026-0" @default.
• W2088101006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11378157" @default.
• W2088101006 hasPublicationYear "2001" @default.
• W2088101006 type Work @default.
• W2088101006 sameAs 2088101006 @default.
• W2088101006 citedByCount "39" @default.
• W2088101006 countsByYear W20881010062012 @default.
• W2088101006 countsByYear W20881010062013 @default.
• W2088101006 countsByYear W20881010062014 @default.
• W2088101006 countsByYear W20881010062015 @default.
• W2088101006 countsByYear W20881010062016 @default.
• W2088101006 countsByYear W20881010062017 @default.
• W2088101006 countsByYear W20881010062018 @default.
• W2088101006 countsByYear W20881010062019 @default.
• W2088101006 countsByYear W20881010062020 @default.
• W2088101006 countsByYear W20881010062021 @default.
• W2088101006 countsByYear W20881010062023 @default.
• W2088101006 crossrefType "journal-article" @default.
• W2088101006 hasAuthorship W2088101006A5003015448 @default.
• W2088101006 hasAuthorship W2088101006A5003358525 @default.
• W2088101006 hasAuthorship W2088101006A5039256755 @default.
• W2088101006 hasAuthorship W2088101006A5080564460 @default.
• W2088101006 hasAuthorship W2088101006A5082246152 @default.
• W2088101006 hasAuthorship W2088101006A5088410101 @default.
• W2088101006 hasAuthorship W2088101006A5091230475 @default.
• W2088101006 hasConcept C100691959 @default.
• W2088101006 hasConcept C118552586 @default.
• W2088101006 hasConcept C134018914 @default.
• W2088101006 hasConcept C170493617 @default.
• W2088101006 hasConcept C185592680 @default.
• W2088101006 hasConcept C24998067 @default.
• W2088101006 hasConcept C2775858608 @default.
• W2088101006 hasConcept C2776885963 @default.
• W2088101006 hasConcept C2777010014 @default.
• W2088101006 hasConcept C2778186239 @default.
• W2088101006 hasConcept C2778460930 @default.
• W2088101006 hasConcept C2779324764 @default.
• W2088101006 hasConcept C2780763569 @default.
• W2088101006 hasConcept C42219234 @default.
• W2088101006 hasConcept C42533223 @default.
• W2088101006 hasConcept C55493867 @default.
• W2088101006 hasConcept C67018056 @default.
• W2088101006 hasConcept C71924100 @default.
• W2088101006 hasConcept C98274493 @default.
• W2088101006 hasConceptScore W2088101006C100691959 @default.
• W2088101006 hasConceptScore W2088101006C118552586 @default.
• W2088101006 hasConceptScore W2088101006C134018914 @default.
• W2088101006 hasConceptScore W2088101006C170493617 @default.
• W2088101006 hasConceptScore W2088101006C185592680 @default.
• W2088101006 hasConceptScore W2088101006C24998067 @default.
• W2088101006 hasConceptScore W2088101006C2775858608 @default.
• W2088101006 hasConceptScore W2088101006C2776885963 @default.
• W2088101006 hasConceptScore W2088101006C2777010014 @default.

• next